Brentuximab vedotin in combination with bendamustine [BRE17]

For treating relapsed or refractory classical Hodgkin lymphoma following failure of at least two prior lines of therapy or relapsed following autologous stem cell transplant paediatric patients aged 8 years and older where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anticancer therapy with brentuximab vedotin and bendamustine will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has biopsy-proven, CD30-positive relapsed or refractory classical Hodgkin lymphoma.
3. The patient is a child* (between 8 years and 17 years of age) and will receive brentuximab vedotin and bendamustine as outlined within the policy. *note there is a separate Blueteq form to be used for brentuximab vedotin and bendamustine in this indication in adults.
4. One of the below options applies to the patient. Please also select the applicable option below:

• Failure of at least 2 prior lines of therapy for classical Hodgkin lymphoma
• Since relapsed following autologous stem cell transplant

5. The patient does not meet ANY of the Exclusion Criteria in the NHS England Policy including the following: i. Previously treated with bendamustine in ii. Less than a partial or a complete response to previous treatment with brentuximab vedotin iii. Contraindications to either brentuximab vedotin or bendamustine iv. Pre-existing neuropathy grade 3 or greater.
6. The patient has a Karnofsky (for patients aged >16 years) OR Lansky (for patients aged <=16 years) performance status >=60
7. The stopping Criteria outlined in the NHS England policy have been agreed with the patient and/or carer before the treatment is started and this has been documented in the patient records.
8. The use of the brentuximab vedotin and bendamustine has been discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.
9. Where a treatment break of more than 6 weeks, the prescribing clinician will complete a treatment break approval form to restart treatment. Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process.
10. For patients aged 18 years and older, Trust policy regarding the use of unlicensed treatments has been followed as this treatment is not licensed in this indication for this age group. Clinicians will need to fully discuss with patients the risks/ benefits of this treatment as compared to the standard funded treatment.
11. Brentuximab vedotin and bendamustine are to be otherwise used as set out in the Clinical Commissioning Policy and Summary of Product Characteristics.

NHS funded From: 24 July 2026

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: NHSE Policy 2404 (NA)

Current Form Version

Note

The data on this page was produced using version 1.406 of the CDF list, downloaded from NHS England’s website on 12 August 2026 at 09:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.